PriceTargets.com logo

Henry Schein - HSIC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $85.58
  • Forecasted Upside: 17.05%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$73.12 As of 03/18/2026 05:00 PM ET
▼ -1.75 (-2.34%)

This chart shows the closing price for HSIC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Henry Schein Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HSIC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HSIC

Analyst Price Target is $85.58
▲ +17.05% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Henry Schein in the last 3 months. The average price target is $85.58, with a high forecast of $100.00 and a low forecast of $61.00. The average price target represents a 17.05% upside from the last price of $73.12.

This chart shows the closing price for HSIC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 13 investment analysts is to hold stock in Henry Schein. This rating has held steady since June 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
2/16/2026
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2026

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/9/2026Leerink PartnersReiterated RatingMarket Perform ➝ Market Perform
2/25/2026Barrington ResearchSet TargetOutperform ➝ Outperform$79.00 ➝ $97.00
2/25/2026UBS GroupBoost TargetNeutral ➝ Neutral$79.00 ➝ $87.00
2/25/2026JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$78.00 ➝ $92.00
2/25/2026MizuhoBoost TargetNeutral ➝ Neutral$81.00 ➝ $88.00
2/25/2026Morgan StanleyBoost TargetUnderweight ➝ Underweight$58.00 ➝ $61.00
2/25/2026Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$76.00 ➝ $87.00
2/24/2026Leerink PartnersBoost TargetMarket Perform ➝ Market Perform$75.00 ➝ $87.00
2/23/2026Robert W. BairdSet TargetNeutral ➝ Outperform$78.00 ➝ $100.00
2/23/2026Robert W. BairdUpgradeNeutral ➝ Outperform$78.00 ➝ $100.00
1/20/2026MizuhoSet TargetNeutral ➝ Neutral$74.00 ➝ $81.00
12/29/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/22/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/16/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/10/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
12/8/2025BarclaysInitiated CoverageOverweight$86.00
12/8/2025BarclaysInitiated CoverageOverweight$86.00
12/4/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/28/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
11/5/2025Barrington ResearchSet TargetOutperform ➝ Outperform$78.00 ➝ $79.00
11/5/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$76.00 ➝ $78.00
11/5/2025Morgan StanleyBoost TargetUnderweight ➝ Underweight$55.00 ➝ $58.00
11/5/2025Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$70.00 ➝ $76.00
11/5/2025EvercoreBoost TargetOutperform ➝ Outperform$83.00 ➝ $90.00
10/31/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
10/22/2025Barrington ResearchReiterated RatingOutperform ➝ Outperform$78.00
10/8/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/27/2025Weiss RatingsReiterated RatingHold (C) ➝ Hold (C)
9/23/2025Barrington ResearchReiterated RatingOutperform ➝ Outperform$78.00
8/26/2025EvercoreUpgradeIn-Line ➝ Outperform$83.00
8/7/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$80.00 ➝ $76.00
8/6/2025UBS GroupLower TargetNeutral ➝ Neutral$75.00 ➝ $70.00
8/6/2025EvercoreLower TargetIn-Line ➝ In-Line$78.00 ➝ $70.00
8/6/2025Barrington ResearchLower TargetOutperform ➝ Outperform$86.00 ➝ $78.00
7/25/2025Stifel NicolausReiterated RatingBuy ➝ Hold$80.00 ➝ $75.00
7/14/2025Leerink PartnersSet Target$75.00
7/14/2025Robert W. BairdDowngradeStrong-Buy ➝ Hold
7/14/2025Robert W. BairdReiterated RatingOutperform ➝ Neutral$82.00 ➝ $72.00
7/9/2025EvercoreBoost TargetIn-Line ➝ In-Line$72.00 ➝ $78.00
5/6/2025Wells Fargo & CompanyLower TargetEqual Weight ➝ Equal Weight$80.00 ➝ $75.00
5/6/2025Barrington ResearchLower TargetOutperform ➝ Outperform$90.00 ➝ $86.00
4/30/2025Piper SandlerLower TargetOverweight ➝ Overweight$83.00 ➝ $77.00
2/26/2025UBS GroupLower TargetNeutral ➝ Neutral$83.00 ➝ $80.00
2/26/2025Barrington ResearchReiterated RatingOutperform ➝ Outperform$90.00 ➝ $90.00
2/14/2025Wells Fargo & CompanyInitiated CoverageEqual Weight$80.00
1/30/2025Barrington ResearchBoost TargetOutperform ➝ Outperform$82.00 ➝ $90.00
1/23/2025Jefferies Financial GroupBoost TargetHold ➝ Hold$77.00 ➝ $80.00
1/6/2025Bank of AmericaUpgradeUnderperform ➝ Buy$69.00 ➝ $84.00
12/4/2024MizuhoInitiated CoverageNeutral$75.00
11/6/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$82.00 ➝ $82.00
10/8/2024EvercoreBoost TargetIn-Line ➝ In-Line$70.00 ➝ $74.00
9/20/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$82.00 ➝ $82.00
8/12/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$88.00 ➝ $80.00
8/7/2024UBS GroupLower TargetNeutral ➝ Neutral$75.00 ➝ $72.00
8/7/2024Robert W. BairdLower TargetOutperform ➝ Outperform$92.00 ➝ $82.00
8/7/2024EvercoreLower TargetIn-Line ➝ In-Line$72.00 ➝ $70.00
8/7/2024Barrington ResearchLower TargetOutperform ➝ Outperform$92.00 ➝ $82.00
7/22/2024Robert W. BairdUpgradeNeutral ➝ Outperform$81.00 ➝ $92.00
7/9/2024EvercoreLower TargetIn-Line ➝ In-Line$75.00 ➝ $72.00
7/5/2024Barrington ResearchReiterated RatingOutperform ➝ Outperform$92.00 ➝ $92.00
6/21/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$86.00 ➝ $86.00
5/8/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$90.00 ➝ $92.00
5/8/2024UBS GroupLower TargetNeutral ➝ Neutral$82.00 ➝ $80.00
3/6/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$82.00 ➝ $88.00
3/6/2024Jefferies Financial GroupBoost TargetHold ➝ Hold$74.00 ➝ $81.00
2/28/2024EvercoreBoost TargetIn-Line ➝ In-Line$79.00 ➝ $83.00
2/28/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$82.00 ➝ $90.00
2/26/2024Leerink PartnersReiterated RatingMarket Perform
2/26/2024Piper SandlerBoost TargetOverweight ➝ Overweight$78.00 ➝ $86.00
2/26/2024Leerink PartnersInitiated CoverageMarket Perform$78.00
12/12/2023JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$71.00 ➝ $82.00
11/27/2023Stifel NicolausReiterated RatingBuy ➝ Buy$75.00
11/14/2023UBS GroupLower TargetNeutral ➝ Neutral$82.00 ➝ $75.00
11/14/2023Barrington ResearchLower TargetOutperform ➝ Outperform$90.00 ➝ $82.00
11/14/2023Morgan StanleyLower TargetUnderweight ➝ Underweight$69.00 ➝ $65.00
11/10/2023Stifel NicolausUpgradeHold ➝ Buy$70.00
11/1/2023Stifel NicolausLower TargetHold ➝ Hold$80.00 ➝ $70.00
10/26/2023Piper SandlerLower TargetOverweight ➝ Overweight$94.00 ➝ $84.00
8/9/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$80.00 ➝ $83.00
8/8/2023Barrington ResearchReiterated RatingOutperform ➝ Outperform$90.00
8/8/2023Stifel NicolausLower Target$85.00 ➝ $80.00
8/8/2023Credit Suisse GroupReiterated RatingOutperform ➝ Outperform$96.00
8/7/2023Bank of AmericaLower Target$76.00 ➝ $75.00
5/10/2023Barrington ResearchLower Target$92.00 ➝ $90.00
3/7/2023UBS GroupBoost TargetNeutral$75.00 ➝ $82.00
2/28/2023Credit Suisse GroupLower TargetOutperform$99.00 ➝ $97.00
2/21/2023Morgan StanleyLower TargetUnderweight$70.00 ➝ $69.00
2/17/2023Barrington ResearchLower TargetOutperform$99.00 ➝ $92.00
2/6/2023Piper SandlerBoost TargetOverweight$85.00 ➝ $97.00
12/21/2022Morgan StanleyLower TargetUnderweight$72.00 ➝ $70.00
11/1/2022William BlairReiterated RatingMarket Perform
9/26/2022Piper SandlerLower TargetOverweight$96.00 ➝ $85.00
8/9/2022EvercoreLower Target$83.00
8/8/2022UBS GroupUpgradeSell ➝ Neutral$80.00
8/3/2022Credit Suisse GroupLower TargetOutperform$100.00 ➝ $90.00
8/3/2022Barrington ResearchLower TargetOutperform$102.00 ➝ $99.00
8/2/2022Piper SandlerLower Target$100.00 ➝ $96.00
7/21/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$93.00 ➝ $85.00
6/17/2022Stifel NicolausLower Target$90.00 ➝ $80.00
6/14/2022Robert W. BairdDowngradeOutperform ➝ Neutral$103.00 ➝ $88.00
5/3/2022William BlairReiterated RatingMarket Perform
2/16/2022Barrington ResearchBoost Target$96.00 ➝ $102.00
2/16/2022Morgan StanleyBoost TargetUnderweight$67.00 ➝ $72.00
2/16/2022Robert W. BairdBoost Target$98.00 ➝ $103.00
2/16/2022Credit Suisse GroupBoost TargetOutperform$90.00 ➝ $100.00
1/31/2022Morgan StanleyInitiated CoverageUnderweight$67.00
1/28/2022Piper SandlerLower Target$98.00 ➝ $95.00
1/7/2022Credit Suisse GroupUpgradeNeutral ➝ Outperform$78.00 ➝ $90.00
11/3/2021Robert W. BairdBoost TargetOutperform$94.00 ➝ $98.00
11/2/2021Piper SandlerBoost TargetOverweight$95.00 ➝ $98.00
8/4/2021Barrington ResearchBoost TargetOutperform$91.00 ➝ $95.00
8/3/2021Piper SandlerBoost TargetOverweight$89.00 ➝ $95.00
5/5/2021Barrington ResearchBoost TargetOutperform$80.00 ➝ $91.00
5/5/2021Robert W. BairdBoost TargetOutperform$79.00 ➝ $90.00
5/4/2021Piper SandlerBoost TargetOverweight$79.00 ➝ $89.00
(Data available from 3/18/2021 forward)

News Sentiment Rating

0.92 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 20 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2025
  • 3 very positive mentions
  • 17 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2025
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/19/2025
  • 11 very positive mentions
  • 22 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2025
  • 0 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2025
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/17/2026
  • 4 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
2/16/2026
  • 46 very positive mentions
  • 35 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
3/18/2026

Current Sentiment

  • 46 very positive mentions
  • 35 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Henry Schein logo
Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
Read More

Today's Range

Now: $73.12
Low: $72.99
High: $74.53

50 Day Range

MA: $77.96
Low: $73.12
High: $83.35

52 Week Range

Now: $73.12
Low: $60.56
High: $89.29

Volume

1,127,243 shs

Average Volume

1,665,457 shs

Market Capitalization

$8.39 billion

P/E Ratio

22.36

Dividend Yield

N/A

Beta

0.88

Frequently Asked Questions

What sell-side analysts currently cover shares of Henry Schein?

The following equities research analysts have issued research reports on Henry Schein in the last twelve months: Barclays PLC, Barrington Research, Evercore Inc, JPMorgan Chase & Co., Leerink Partners, Mizuho, Morgan Stanley, Piper Sandler, Robert W. Baird, Stifel Nicolaus, UBS Group AG, Wall Street Zen, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for HSIC.

What is the current price target for Henry Schein?

0 Wall Street analysts have set twelve-month price targets for Henry Schein in the last year. Their average twelve-month price target is $85.58, suggesting a possible upside of 17.0%. Robert W. Baird has the highest price target set, predicting HSIC will reach $100.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $61.00 for Henry Schein in the next year.
View the latest price targets for HSIC.

What is the current consensus analyst rating for Henry Schein?

Henry Schein currently has 1 sell rating, 6 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in HSIC, but not buy more shares or sell existing shares.
View the latest ratings for HSIC.

What other companies compete with Henry Schein?

Other companies that are similar to Henry Schein include Cooper Companies, IDEXX Laboratories, Masimo, Merit Medical Systems and AMN Healthcare Services. Learn More about companies similar to Henry Schein.

How do I contact Henry Schein's investor relations team?

Henry Schein's physical mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company's listed phone number is (631) 843-5500 and its investor relations email address is [email protected]. The official website for Henry Schein is www.henryschein.com. Learn More about contacing Henry Schein investor relations.